Advertisement

Topics

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

08:19 EST 11 Dec 2017 | Labiotech.eu

ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech ADC Therapeutics is one of our top biotechs of the year after it brought in a massive $200M (€170M) fundraising round. The company develops antibody-drug conjugates (ADCs) ...

This awesome article New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

NEXT ARTICLE

More From BioPortfolio on "New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...